Director Alison Cornell Buys Nearly $100K in Zivo Bioscience Stock
ZIVO sits 29% above its 52-week low of $6.953.
Summary
Zivo Bioscience Director Alison A. Cornell made an open market purchase of company stock totaling approximately $99,995, signaling confidence in the company.
Key Events · Ownership and Investor Activity · ZIVO
-
Director Stock Purchase
Alison A. Cornell, a Director of Zivo Bioscience, acquired 11,709 shares of common stock in an open market transaction on January 26, 2026, for a total value of approximately $99,995.
-
Insider Accumulation Trend
This purchase by a director follows a recent open market buy of similar value by the company's President and CEO, indicating a broader trend of insider accumulation.
Analysis · ZIVO · Life Sciences
Director Alison A. Cornell's open market purchase of approximately $99,995 in Zivo Bioscience stock is a notable signal of confidence. This transaction, representing a significant investment for a director, suggests an insider belief in the company's future prospects or that its shares are currently undervalued. This purchase follows a recent similar-sized open market buy by the President and CEO, indicating a pattern of insider accumulation within the company.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZIVO was trading at $9.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $35M. The 52-week trading range was $6.95 to $22.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.